Introduction
Stem cell transplantation (SCT) is an established treatment for various hematological disorders. Usually, the patient's hematopoiesis is ablated by the combination of the conditioning regimen and the allogeneic effect of the graft and the presence of recipient cells in the blood can be a sign of graft failure or of the recurrence of the original disease. Therefore, assays capable of determining the donor or recipient origin may help to assess the success or failure of the transplantation. Information about the quantity of recipient cells in the blood may help to adjust the therapy during first weeks after transplant (graft take) or to diagnose a relapse in patients transplanted for leukemia or myelodysplastic syndrome (MDS). Furthermore, the response of a patient in relapse to a donor lymphocyte infusion can be monitored to decide whether a second dose of allogeneic lymphocytes should be given or not.
In our transplantation unit, all patients transplanted with an allogeneic graft are monitored for the occurrence of mixed chimerism. For patients having received a myelobablative conditioning regimen, the first blood sample is tested between day 15 and 20, followed by a second sample around day 30. Then, when the graft take has occurred, patients are tested at regular intervals (at 2, 3, 6 and 12 months) during the first year and approximately once per year thereafter. Patients having received a non-myeloablative conditioning regimen are monitored more frequently. During the first 2 months after transplantation, they are tested weekly, then every other week until day 100, every other month for up to 1 year and three to four times per year thereafter. Patients treated with DLI are monitored on a weekly basis after the start of the adoptive therapy until full donor chimerism is achieved. In case of suspicion of relapse, chimerism analysis is also part of the diagnostic procedure and is continuously compared to other clinical and molecular markers such a BCR-ABL in patients with recurrent chronic myeloid leukemia (CML). Here, as a contribution to the current debate in Leukemia 1-10 we present our in-house method as applied to 111 stem cell-transplanted patients.
I. Assay characteristics
PCR amplification of minisatellite or microsatellite DNA regions combines sensitivity with the possibility to quantify the number of cells of recipient origin. [11] [12] [13] [14] [15] Owing to their high degree of polymorphism, a few short tandem repeat markers (STRs) are sufficient to discriminate the bulk of the donorrecipient pairs even when the two come from the same family. Therefore, these markers are very suitable for routine laboratory tests. We use five STR markers (Table 1) , as well as amelogenin amplified with primers coupled to fluorochromes to enable quantification after capillary electrophoresis. Before analysis, blood samples are Ficolled to be able to analyze the granulocytes separately from the mononuclear cells (MNC). The reason for this is that many of the patients transplanted in our center have received in vitro T cell-depleted stem cell grafts. In such patients, recipient T cells may persist in the absence of a recipient hematopoiesis [14] [15] [16] and therefore, the detection of recipient DNA only in the mononuclear fraction is not necessarily a sign of a recurrent disease. Approximately 2-3 × 10 6 MNC as well as the upper part of the granulocyte/erythrocyte fraction are frozen at −20°C until tested.
II. Protocol
DNA is prepared by standard high salt extraction from the frozen MNC, as well as from 300 l of the frozen granulocyte/erythrocyte fraction that is washed several times to remove most of the hemoglobin. Considerably higher volumes may be used in patients with very low blood counts. Thereafter, the DNA is quantitated by spectrophotometry and dissolved at 100 ng/l in Tris HCl 1 mM pH 7.5 + 0.1 mM EDTA buffer. One l is then PCR amplified (210 s at 94°C, five cycles 30 s at 94°C/30 s at 61°C/1 min at 72°C, nine cycles 30 s at 94°C/30 s at 59°C/1 min at 72°C, 13 cycles 30 s at 94°C/30 s at 57°C/70 s at 72°C followed by a final elongation of 6 m at 72°C) in a total volume of 20 l PCR buffer (50 mM KCl, 100 g/ml BSA, 10 mM Tris HCl pH 8.8) containing 6 pmol of the respective set of primers (see Table 1 ), 200 M dNTP and 0.5 U of Taq DNA polymerase with the MgCl 2 concentration adapted to the set of primers (SE33 at 1 mM, D16S539, D20S481, FGA at 1.25 mM and D11S554 and Amelogenin at 1.5 mM). Then 0.5-1 l of PCR product is mixed with 12 l of deionized formamide and 0.4 l Genescan TAMRA 500 standard (Applied Biosystems, Rotkreuz, Switzerland), denatured by boiling for 3 min and spun down after 3 min on ice. Analysis is performed by placing the tubes in the sample rack of an ABI Prism 310 Genetic Analyzer equipped with a 47 cm × 50 m capillary with POP-4 polymer (Applied Biosystems). The PCR products of different length, visible through the various fluorochromes with which the oligos had been marked, are quantitated by assessing the surface areas of the peaks using the Genescan program.
III. Time requirement
In our hospital, we perform our routine chimerism analysis on a fixed day in the week. Accordingly, all blood samples are collected, Ficolled and kept at −20°C until tested. However, if results are needed urgently, we are able to send our data at the end of the next working day.
IV. Specificity/informativeness
In our routine assay we use the five STRs 17-19 depicted in Table 1 , as well as amelogenin 20 to discriminate between donor and patient cells. Notwithstanding the fact that most of our patients are transplanted with stem cells of their HLAidentical sibling, this limited set of STRs resolved allelic differences in 109/111 of the combinations. Although usually donor and recipient can be discriminated by more than one locus, routine monitoring is done with one STR only, except for the first 1-2 blood samples taken immediately after transplantation and the first samples after a relapse when, where possible, two STRs are used.
Most donor-recipient pairs show allelic differences for several of the loci we use in our assay. However, for technical as well as practical reasons, most patients are monitored with either SE33 (ACTBP2) or D11S554. These two STRs are preferred in the first place because of their high polymorphism (23 alleles in our patient population), as well as because none of the individual alleles occur at a frequency higher than 13% (fourth column, Table 2 ). As a result, most individuals are heterozygous and most pairs can be discriminated by these two STRs. Obviously, the choice of the STR does not solely depend on the degree of polymorphism. Interpretation of the percentage of donor and recipient DNA can only be precise when the respective peaks are clearly distinguishable and when the size of the respective PCR products is comparable. Thus, when the patient's allele, although different in size, migrates in or close to the area of the stutter bands of the donor's allele, another STR is preferred. Furthermore, when the PCR products of the patient and donor alleles differ too much in size so that owing to the size-dependent PCR effiLeukemia cacy, quantitation gets cumbersome, another STR may be selected. However, it should be noted that in such combinations, this inconvenience might be accepted when the recipient allele is the smallest in size. In particular in patients transplanted for leukemia who are being monitored for relapses, we prefer to use a small STR that is efficiently amplified. Obviously, in these patients the priority is also the detection of low amounts of recipient cells, when this comes at the cost of the loss of the quantitative aspect of the test. Our experience with the five STRs in 111 donor-recipient pairs is shown in column 6-11 of Table 2 , where the results of the respective STRs are ordered from left to right according to their potential to discriminate recipient from donor cells. The sixth column (RD) shows the percentage of pairs of which for the respective STR, at least one of the recipient alleles and one of the donor alleles are outside a stutter region and close enough to each other to be amplified with a comparable efficacy. The seventh column (R) shows the percentage of pairs with a small recipient allele outside a stutter region. As argued above, we feel that except when exact quantification is the priority, this configuration is also acceptable. When recipient and donor alleles are configured as in column 8-11, the STR is never selected. The alleles of the pairs in column 8 are distinguishable, but the large size of the PCR product of the recipient allele hampers the sensitivity of the test, while the allele configuration in columns 9-11 excludes a correct interpretation either because the recipient alleles are in a stutter region (S), because only donor specific alleles are present (D) or because donor and recipient express the same alleles (NI). Because SE33 gives interpretable (column RD + R) results in 49% and D11S554 in 45% of the patients, most (78%) of the patients are monitored with one of these STRs. When both STRs are equally discriminative, D11S554 is preferred because it appears to be slightly more sensitive than SE33 (column 12). In the other patients, when a choice is available, we prefer FGA to D16S539 that typically has a considerable number of stutter bands and to D20S481 for which in a number of cases the PCR generates double bands for a single allele. Only in one of the 111 pairs, we were compelled to use amelogenin, which in our hands gives results that are hard to quantify, while two of 111 pairs were not resolved.
V. Sensitivity
The sensitivity depends more on the size of the allele of interest than on the characteristics of the locus chosen. In practice, for approximately one-third of our patients, we were able to % RD, Percentage of pairs with clearly distinguishable recipient and donor bands (outside their respective stutter region) for whom the percentage of chimerism can be assessed accurately owing to the comparable sizes of the recipient and donor alleles; % R, Recipient band not in stutter and efficiently amplified (low threshold) owing to the relatively small size of the allele; % rd, Recipient and donor bands not in stutter, but of a size that makes quantification cumbersome; % S, Recipient/donor-bands close to or in stutter region; % D, only donor specific bands; % NI, not informative (the same alleles for recipient and donor). a The sensitivity may be lower for large size PCR products (alleles), but in such cases, the STR is not selected for the donor-recipient combination.
Leukemia
select an STR that detects between 1-2% of patient cells, for half of our patients the detection level was around 3%, while for the remaining 20%, the detection level was around 5%.
VI. Reproducibility and quality control
In all assays a 100% donor, a 100% patient as well as the four last samples tested are included as controls. The latter allowed surveying the reproducibility of the method which was extremely high. All the samples containing between 10 and 100% of donor cells gave identical (variation Յ5%) results when tested the second time. Obviously, for samples with 1-10% of chimerism, this variation could be higher but samples in which low amounts (3-5%) of chimerism had been detected always gave comparable results when retested. Only samples with 1-2% of chimerism are sometimes tested negative a second time. Therefore, samples containing just above threshold amounts of patient DNA are regularly tested as a sensitivity control.
VII. Costs
The costs of reagents is highest when the patient is monitored for the first one to three times because the optimal STR still has to be selected and the number of internal controls is considerable. We estimate that the cost for the first three samples is around 50 Euros. Thereafter, the costs are around 7 Euros per sample, which includes the quality control mentioned above.
VII. Discussion
The occurrence of mixed chimerism of the hematological lineages after SCT is informative about the course of the transplantation. At present, most laboratories use a PCR amplification of microsatellite DNA regions to discriminate between patient and donor cells. This method is suited for a routine laboratory because owing to the large polymorphism of the STRs, only a few loci have to be tested. The sensitivity of the method is adequate. In our laboratory, the threshold for the detection of patient cells is around 3%. Before transplantation, the best STR is selected for each donor-recipient combination. This choice is mainly based on the characteristics of the recipient allele that has to be clearly distinguishable from the closest donor allele as well as of a small enough size to warrant a detection threshold of around 3%. In most combinations, this could be achieved with only two STRs (SE33 and D11S554). Only in a few cases, when for instance the STR that discriminated the donor and patient most clearly, did not give the desired sensitivity, compromises had to be found. Such patients were often monitored with an additional STR or where possible, with amelogenin to obtain interpretable results. The detection threshold also dictates the value of the method, as well as how the results should be interpreted. Obviously, the method has its limitations for monitoring patients at risk of relapse. This is most clear for multiple myeloma patients who have usually few malignant cells in their blood or for CML patients who, in our center, are also monitored for BCR-ABL. With the two log higher sensitivity of the PCR for BCR-ABL, it has now become apparent that in approximately one of four of our CML patients, the relapse had occurred without being detected by the STR PCR. However, chimerism testing for leukemic relapses is often quite useful as confirmatory test, particularly when the hematological diagnosis is doubtful. This may be the case when a phenotype analysis detects blasts uncharacteristic of the original diseases or for instance in MDS. In the latter disease, especially in the absence of chromosomal abnormalities, monitoring of chimerism does allow diagnosing a relapse prior to a distinct clinical relapse. Therefore, monitoring of mixed chimerism is most useful in situations where quantitation of donor and or recipient cells is essential. For instance, in patients receiving mini-transplants, the number of donor cells is crucial and has to be quantitated in the patients blood that still contains high numbers of recipient cells indistinguishable by their phenotype. Another example is when after a relapse, an adoptive immunotherapy is considered. Such a therapy aimed at the eradication of hematological cells of recipient origin should only be given if by STR analysis some donor granulocytes are still detected. 21 This is clearly the proof that some donor hematopoiesis is still active so that the donor lymphocyte infusion can be given without the risk of inducing marrow aplasia.
In conclusion, monitoring of chimerism in patients after SCT provides crucial information on the clinical status of the patient. A still wider application of the technique in the routine follow-up of patients is to some extent hampered by technical aspects such as reproducibility and sensitivity. During the last 2 years, several groups 1 have presented their in-house methods in the context of the 'Round- Table Debate on Chim- erism Testing' in this journal. This discussion will certainly help to optimize the method, which should ultimately lead to the standardization of chimerism testing in the laboratories involved in SCT.
